ALX ONCOLOGY HOLDINGS INC (ALXO)

Company Profile

ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 71 full-time employees. The company went IPO on 2020-07-17. The firm is focused on helping patients fight cancer by developing a pipeline of product candidates based on protein engineering and oncology led by the cluster of differentiation 47 (CD47) blocker. The company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), head and neck squamous cell carcinomas (HNSCC), gastric and breast cancer. The Company’s preclinical program is focused on developing ALTA-002, which combines its signal regulatory protein alpha (SIRPa) and toll-like receptor 9 agonist antibody conjugate (TRAAC).

Company Info

ALX ONCOLOGY HOLDINGS INC

323 Allerton Avenue

South San Francisco CALIFORNIA 94010

P: 16504667125

CEO: Jaume Pons

Employees: 71

Website: https://alxoncology.com/